532results about "Peptide sources" patented technology

The invention discloses a human albumin binding peptide 1E3 and application of the human albumin binding peptide 1E3 in promoting purification of human albumin, and belongs to the technical field of polypeptides. The human albumin binding peptide comprises an amino acid sequence as shown in SEQ ID NO. 1; and / or an amino acid sequence of a fusion protein with the same function, which is obtained by connecting tag protein to the N terminal and / or C terminal of the amino acid sequence as shown in SEQ ID NO.1. The human albumin binding peptide has extremely high affinity with human albumin and can be used for separating and purifying a human albumin solution, and the purity of the purified human albumin far exceeds the pharmacopoeia standard and can reach 99.99% or above. The method is good in safety and stable in process, and has a wide application prospect in the aspect of separation and purification of the human albumin.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

The present disclosure relates to anti-glyco-LAMP1 antibodies and antigen-binding fragments thereof that specifically bind to cancer-specific glycosylation variants of LAMP1, as well as related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to the use of antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The present invention pertains to the technical field of biomedicine, and specifically relates to a gene delivery system and use thereof in the preparation of a tumor therapeutic drug. The present invention relates to a technical means for inducing differentiation of tumor cells into mature cells, which utilizes messenger ribonucleic acid to regulate the expression of HNF4α in tumor cells, inhibits the malignant phenotype of malignant solid tumor cells, and achieves the effect of treating malignant solid tumors, thereby being applied to a preparation method and use of a solid tumor drug.

Provided is a nucleic acid structure which enhances an antigen-specific immune response. The nucleic acid structure comprises a polynucleotide encoding a SNARE protein selected from the group consisting of VAMP7, GOSR2, STX10, STX18, BNIP1, STX7, VTI1A, STX16, STX5, GOSR1, STX8, STX12, VAMP8 and SEC22B, and a polynucleotide encoding an antigen.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present invention relates to a recombinantly constructed protein that is useful for analytical assay, particularly for determining the presence of rhabdovirus specific antibody in biological samples obtained from individuals.More specifically, the present invention relates to a polypeptide that comprises the ectodomain of rhabdovirus glycoprotein and the heterologous multimerization domain connected to said ectodomain.In one example, there is provided a fusion protein of formula xyz (wherein x consists of or comprises the ectodomain, which may not contain furin cleavage site, y is a linker site, and z is the heterologous multimerization domain that may be selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence and avidin sequence).

Compositions and methods are provided for treating diseases associated with abnormal glycosylation of cell surface molecules and the expression of tumor-associated carbohydrate antigen (TACA). Also provided are a bispecific fusion protein and a chimeric antigen receptor (CAR) specific for a tumor-associated carbohydrate antigen (TACA-CAR), a vector encoding the TACA-bispecific fusion protein and the TACA-CAR, and a recombinant cell comprising the TACA-bispecific fusion protein and the TACA-CAR.

Disclosed herein are antibodies and antigen-binding fragments thereof that specifically bind human CD4. Also disclosed are fusion proteins comprising Paramyxoviridae glycoprotein G and CD4 antibodies for targeting and transducing cells expressing CD4. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The present invention pertains to: a granzyme B variant having enhanced protease activity and / or enhanced tolerance against an inhibitory factor; a polynucleotide encoding the granzyme B variant; a cell expressing the granzyme B variant; a pharmaceutical composition comprising the cell expressing the granzyme B variant; and a pharmaceutical composition comprising the granzyme B variant. In some embodiments, the pharmaceutical composition can be used in combination with a cell expressing a chimeric receptor and / or an antigen-binding molecule.

Therapeutic agents that can place bulky proteins, such as CD45, CD148, and CD43, at the center of the cellular interface between graft cells and CD45-positive host effector cells (e.g., T cells, NK cells, B cells, or dendritic cells) are disclosed, as are methods of their use and products made with such therapeutic agents. The therapeutic agents prevent or inhibit the formation of functional immunological synapses (including physiological SMACs). They also result in the continuous dephosphorylation of signaling pathways.

The present invention relates to an improved protein-based biosensor suitable for the detection of one or more target molecules in a sample. The biosensor is fully reversible with a dynamic range suitable for analytical and diagnostic applications. The biosensor of the present invention can be used in synthetic biology, for example in the construction of artificial cellular or extracellular signaling networks.

The present invention relates to the use of a polypeptide in resisting addiction and its relapse.The present invention provides the use of a polypeptide in preparing a medicament for treating and / or preventing substance addiction and its relapse.The polypeptide consists of at least 11 consecutive amino acid residues of the sequence shown in SEQ ID NO:1 and comprises the sequence shown in SEQ ID NO:2.Furthermore, the present invention relates to the use of said polypeptide, the use of a nucleic acid molecule, the use of an expression vector and the use of a host cell, as well as a complex comprising said polypeptide.

The present invention relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. Specifically, the present invention relates to the immunotherapy of cancer, particularly hematological tumors such as acute myeloid leukemia (AML). Furthermore, the present invention relates to tumor-associated T cell peptide epitopes that can be used, for example, as active pharmaceutical ingredients in vaccine compositions to stimulate anti-tumor immune responses or that can stimulate ex vivo T cells for transfer into patients. Peptides bound to major histocompatibility complex (MHC) molecules, and even the peptides themselves, may be targets for antibodies, soluble T cell receptors, and other binding molecules.

This peptide includes an amino acid sequence represented by formula A1 or an amino acid sequence in which one or more amino acid residues in the amino acid sequence represented by formula A1 have been substituted, deleted, added, or inserted. A1: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15

To provide compositions and particles for payload delivery.SOLUTION: The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell. The present invention provides a composition comprising e.g., a carrier capable of entering a polarized epithelial cell or transcytosing across a polarized epithelial cell; and a heterologous payload, a molar ratio of the heterologous payload to the carrier being greater than 1:1.SELECTED DRAWING: None

To provide peptide-based vaccines for inducing immune response and production methods and uses thereof.SOLUTION: The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject. The present inventors have developed novel compositions and methods of manufacturing peptide-based vaccines that overcome at least one of the limitations of current peptide-based vaccine approaches. The novel peptide-based vaccine compositions and methods of manufacturing disclosed herein account for the variability in the physical and chemical properties of peptide antigens and are therefore generalizable for any peptide antigen.SELECTED DRAWING: None

An isolated peptide for regulating intracellular protein degradation that includes a linker sequence fused to a C-end degron peptide and, optionally, a caging molecule bonded to the carboxyl group of a C -terminal alanine residue. Also disclosed is a method for temporal control of protein degradation that relies on fusing a protein of interest at its C- terminus to the degron peptide having a caging molecule, and a method for high-fidelity gene editing that utilizes an RNA-dependent endonuclease modified at the C -terminus with the caged isolated peptide. A fusion protein for high-fidelity gene editing is further provided.

To provide AAV having modified transduction ability, the AAV including in its structure, various kinds of transducing genes including a clinically important transducing gene for a patient who requires a transducing gene.SOLUTION: There are provided: an isolation modification VP1 protein of an adeno-associated virus serotype 5 (AAV5) capsid, including one or more amino acid replacements for improving transduction efficiency, relative to VP1 protein of a wild type AAV5 capsid; and capsid and vector based on the isolation modification VP1 protein.SELECTED DRAWING: None

This invention provides artificial nucleic acid molecules that enhance the efficacy of therapeutic nucleic acids. [Solution] The present invention provides an artificial nucleic acid molecule comprising a novel combination of 5' and 3' untranslated region (UTR) factors. The nucleic acid molecule of the present invention is preferably characterized by increased expression efficiency of a coding region operably linked to the UTR factors. The artificial nucleic acid can be used for the treatment or prevention of various diseases. The present invention further provides (pharmaceutical) compositions, vaccines, and kits comprising the artificial nucleic acid molecule. Furthermore, an in vitro method for preparing the artificial nucleic acid molecule of the present invention is provided.

A fusion protein for an auxin degradation determining subsystem for controlling the degradation of a target protein derived from a non-plant eukaryotic cell, the fusion protein being a fusion protein of a degradation tag and a protein having an affinity for the target protein, the dissociation tag comprises at least a portion of the Aux / IAA family protein and has an affinity for the TIR1 family protein-auxin or auxin analog complex.

To provide FMS-like tyrosine kinase 3L (FLT3L) fused to human cytokines, which is use in, e.g., cancer treatment.SOLUTION: The present invention provides a chimeric protein comprising a targeting moiety which comprises a single copy of FMS-like tyrosine kinase 3 ligand (FLT3L), or a portion thereof. In various embodiments, the targeting moiety functionally modulates an antigen or receptor of interest. In some embodiments, the targeting moiety binds but does not functionally modulate the antigen or receptor of interest. In some embodiments, the targeting moiety comprises a single copy of the extracellular domain of FLT3L, or respective portions thereof.SELECTED DRAWING: Figure 1

The invention relates to an immune system humanized mouse biological system for preparing a fully humanized monoclonal antibody and a method for preparing the fully humanized monoclonal antibody. The method comprises the following steps: using a constructed immune system humanized mouse and a VLP chimeric antigen; the HSC immune system humanized mouse is an immunodeficient mouse transplanted with human immune cells, the human immune cells are reconstructed, and antigen-specific B cells and fully humanized antibodies can be generated in the immune system humanized mouse by using a VLP chimeric antigen without firstly activating DC and antigen-specific T cells. In addition, by coupling a VLP antigen and a target antigen, a specific B cell and a fully human antibody of any target can be generated.

The present disclosure generally relates to therapies involving immune effector cells, such as T cells, engineered to express an antigen receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). It is demonstrated herein that such antigen receptor-engineered immune effector cells can be generated in vitro / ex vivo and in vitro by delivering a nucleic acid encoding an antigen receptor for genetic modification to cells using particles containing the nucleic acid and a targeting molecule for targeting the immune effector cells, where the targeting molecule is a designed ankyrin repeat protein (DARPin). In particular, DARPins are described herein as high-affinity binders for CD8 binding to the CD8 receptor on human and non-human primate (NHP) cells. Nanoparticles functionalized with CD8-targeting DARPins (CD8-DARPins) have been shown to target human CD8 in vitro and in vivo. + Genes can be delivered exclusively and specifically to T cells.

To provide polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, and further to provide methods of making and using the same.SOLUTION: Provided are: polypeptides including specific sequences or an amino acid sequence that is at least 90% identical to an amino acid sequence of any combination thereof; or a polypeptide including specific sequences or an amino acid sequence of any combination thereof. In some embodiments, an FN3 domain does not naturally exist. In some embodiments, the FN3 domain binds to human CD71 at a site on CD71 that does not compete with transferrin binding to CD71.SELECTED DRAWING: None

This invention provides compounds and methods for regulating dmpk expression and treating diseases and conditions in which dmpk plays an active role. [Solution] A transcription modulator molecule is provided having a first end, a second end, and an oligomeric skeleton, wherein a) the first end includes a DNA-binding portion that can non-covalently bind to a nucleotide repeat sequence GAA, b) the second end includes a protein-binding portion that binds to a regulatory molecule that modulates the expression of a gene containing the nucleotide repeat sequence GAA, and c) the oligomeric skeleton includes a linker between the first end and the second end.

The present invention relates to modified bacteria and plasmids (e.g. conjugative plasmids) which are engineered to express auxins and auxin-like molecules (ALMs), to pharmaceutical compositions containing them and their use in the treatment of various metabolic and cardiovascular diseases.